Efficacy of Neonatal HBV Vaccination on Liver Cancer and Other Liver Diseases over 30-Year Follow-up of the Qidong Hepatitis B Intervention Study: A Cluster Randomized Controlled Trial

2014 PLoS Medicine 148 citations

Abstract

Neonatal HBV vaccination was found to significantly decrease HBsAg seroprevalence in childhood through young adulthood and subsequently reduce the risk of PLC and other liver diseases in young adults in rural China. The findings underscore the importance of neonatal HBV vaccination. Our results also suggest that an adolescence booster should be considered in individuals born to HBsAg-positive mothers and who have completed the HBV neonatal vaccination series. Please see later in the article for the Editors' Summary.

Keywords

MedicineVaccinationHepatitis BPopulationHBsAgHepatitis B virusRandomized controlled trialLiver cancerFulminant hepatitisInternal medicineHepatitis B vaccinePediatricsImmunologyHepatitisCancerEnvironmental healthVirus

Affiliated Institutions

Related Publications

Publication Info

Year
2014
Type
article
Volume
11
Issue
12
Pages
e1001774-e1001774
Citations
148
Access
Closed

External Links

Citation Metrics

148
OpenAlex

Cite This

Chunfeng Qu, Taoyang Chen, Chunsun Fan et al. (2014). Efficacy of Neonatal HBV Vaccination on Liver Cancer and Other Liver Diseases over 30-Year Follow-up of the Qidong Hepatitis B Intervention Study: A Cluster Randomized Controlled Trial. PLoS Medicine , 11 (12) , e1001774-e1001774. https://doi.org/10.1371/journal.pmed.1001774

Identifiers

DOI
10.1371/journal.pmed.1001774